Last reviewed · How we verify
Tissueblue (BRILLIANT BLUE G)
Tissueblue works by binding to the P2X purinoceptor 7, a specific receptor on cells, to reveal or stain tissues.
At a glance
| Generic name | BRILLIANT BLUE G |
|---|---|
| Sponsor | Dutch Ophthalmic |
| Drug class | Disclosing Agent [EPC] |
| Target | P2X purinoceptor 7 |
| Modality | Small molecule |
| Therapeutic area | Ophthalmology |
| Phase | FDA-approved |
| First approval | 2019 |
Mechanism of action
TissueBlue 0.025% Mechanism of action section. Brilliant Blue has been shown to selectively stain the ILM, but not the epiretinal membrane nor the retina, making it easier to visualize the membrane for removal, although the exact mechanism of this selectivity has not been elucidated.
Approved indications
- Staining method
Common side effects
- retinal break
- retinal tear
- retinal hemorrhage
- retinal detachment
- cataracts
Key clinical trials
- Mechanical Properties of the Internal Limiting Membrane and Intraoperative Utility of Brilliant Blue g (Bbg) and Indocyanine Green (Icg) Assisted Chromovitrectomy
- Safety and Efficacy of Double Staining With Brilliant Blue G for Macular Surgery (PHASE3)
- Macular Micro Vascular Changes Following Macular Hole Repair : Optical Coherence Tomography Angiography Study (NA)
- Safety and Efficacy Evaluation of Two Different Brilliant Blue G Dyes as Staining Agent in Vitreo Retinal Surgery.
- Internal Limiting Membrane Peeling-reposition to Treat Idiopathic Macular Holes (NA)
- Outcomes of Extensive Brilliant Blue G-Assisted Internal Limiting Membrane Peeling in Proliferative Vitreoretinopathy
- Infracyanine Green vs Brilliant Blue G in Macular Hole Inverted Flap Surgery: A Swept Source OCT Analysis. (NA)
- Outcomes Based on the Pre-operative Integrity of IS/OS Junction in Idiopathic Epimacular Membrane Surgery
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| FDA label | Mechanism, indications, dosing, boxed warnings, drug interactions |
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Tissueblue CI brief — competitive landscape report
- Tissueblue updates RSS · CI watch RSS
- Dutch Ophthalmic portfolio CI